Zacks: Analysts Set $27.33 Target Price for Personalis (NASDAQ:PSNL)

Personalis (NASDAQ:PSNL) has been given a consensus broker rating score of 1.88 (Buy) from the four brokers that cover the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a hold rating and two have issued a strong buy rating on the company.

Brokers have set a 12 month consensus target price of $27.33 for the company and are expecting that the company will post ($0.25) earnings per share for the current quarter, according to Zacks. Zacks has also given Personalis an industry rank of 73 out of 256 based on the ratings given to related companies.

Several research firms have recently weighed in on PSNL. Cowen began coverage on shares of Personalis in a research report on Monday, July 15th. They issued an “outperform” rating for the company. Bank of America began coverage on shares of Personalis in a research report on Monday, July 15th. They issued a “neutral” rating and a $27.00 target price for the company. Oppenheimer began coverage on shares of Personalis in a research report on Monday, July 15th. They issued an “outperform” rating and a $29.00 target price for the company. Morgan Stanley began coverage on shares of Personalis in a research report on Monday, July 15th. They issued an “overweight” rating and a $28.00 target price for the company. Finally, CIBC began coverage on shares of Personalis in a research report on Monday, July 15th. They issued an “outperform” rating and a $29.00 target price for the company.

In other Personalis news, Director Ken Ludlum acquired 70,000 shares of the stock in a transaction that occurred on Monday, June 24th. The stock was acquired at an average price of $17.00 per share, with a total value of $1,190,000.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Several large investors have recently made changes to their positions in PSNL. Board of Trustees of The Leland Stanford Junior University bought a new stake in shares of Personalis during the 2nd quarter valued at about $38,749,000. JPMorgan Chase & Co. bought a new stake in shares of Personalis during the 2nd quarter valued at about $17,685,000. Janus Henderson Group PLC bought a new stake in shares of Personalis during the 2nd quarter valued at about $13,554,000. Laurion Capital Management LP bought a new stake in shares of Personalis during the 2nd quarter valued at about $8,472,000. Finally, Price T Rowe Associates Inc. MD bought a new stake in shares of Personalis during the 2nd quarter valued at about $8,005,000. 4.06% of the stock is owned by institutional investors and hedge funds.

Shares of PSNL traded up $0.67 during midday trading on Thursday, hitting $16.92. The company had a trading volume of 261,439 shares, compared to its average volume of 468,913. The firm has a 50 day moving average price of $21.03. Personalis has a 52 week low of $14.25 and a 52 week high of $31.88.

Personalis (NASDAQ:PSNL) last released its earnings results on Tuesday, August 13th. The company reported ($0.89) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.58). The firm had revenue of $15.80 million for the quarter, compared to the consensus estimate of $14.92 million. The firm’s quarterly revenue was up 79.5% on a year-over-year basis. As a group, sell-side analysts expect that Personalis will post -0.93 earnings per share for the current year.

Personalis Company Profile

Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics.

Featured Story: Quantitative Easing

Get a free copy of the Zacks research report on Personalis (PSNL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Personalis (NASDAQ:PSNL)

Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.